RNA Outsourcing Resources

31. Addressing Challenges In mRNA Drug Development And Manufacturing

    mRNA-based drug products serve as an ideal platform for use in infectious disease, protein replacement, and immuno-oncology applications due to the simplicity of manufacturing and robust immune response.

32. Solving Aseptic Filling Challenges For Your Advanced Therapeutics 8/20/2025

    Explore aseptic filling workcells, modalities, agency approvals, and insights from six expert users that offer a peer-driven look at industry innovation and benchmarks.

33. Enhancing Preclinical Analytics to Drive Clinical Success 12/9/2025

    Bioanalysis is crucial for biopharma success. Here, Dash Bio’s Ander Tallett discusses selecting a bioanalysis CRO and collaborating effectively for assay results that accelerate drug development.

34. Transparent Pricing In Bioanalysis: A Feature, Not A Bonus 3/9/2026

    Unclear CRO pricing leaves small biotechs vulnerable to budget swings. Transparent, itemized costs cut financial risk, sharpen planning, and build trust by setting expectations from the start.

35. Expertise In RNA Therapies: Client Success Stories 2/17/2023

    Learn how to navigate the complex challenges of accelerating therapies through clinical development to regulatory approval and commercialization.

36. 5 Outdated Practices Holding Back Modern Bioanalysis 10/20/2025

    Bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex modern therapies.

37. Bridging The Skills Gap In Biopharma 6/3/2020

    Employees must have the skills to effectively execute on process development and manufacturing operations. How do you ensure they are updated on complex bioprocessing techniques and technologies?

38. Getting CMC Right For Emerging Technologies 12/20/2023

    Establishing a chemistry, manufacturing, and controls strategy that proves a clinical program is tightly controlled and can address risk is critical to avoiding the pitfalls that stall many promising therapeutics.

39. How To Unlock The Secret To Repeatable, Scalable Low Turnover 6/7/2024

    Here, we explore the evolution of a 10-year partnership and extrapolate the principles that create cohesive teams and minimize turnover.

40. The M.O. Behind Choosing A CDMO: Three Considerations For New Drug Developers 11/29/2021

    The greatest challenge in drug development can be finding a team capable of carrying a molecule through the complexities that lie between the research lab and the patient’s bedside. Discover three considerations that build a foundation for partnership.